Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
暂无分享,去创建一个
T. Bathala | E. Jonasch | P. Sharma | Jianjun Gao | P. Corn | A. Siefker-Radtke | M. Campbell | A. Shah | A. Zurita | A. Aparicio | P. Msaouel | S. Subudhi | N. Tannir | B. Siddiqui | Jennifer R. Wang | J. Gheeya | S. Goswami | D. Surasi | R. Goswamy | J. Wang | Padmanee Sharma